[HTML][HTML] New vaccine technologies to combat outbreak situations
Ever since the development of the first vaccine more than 200 years ago, vaccinations have
greatly decreased the burden of infectious diseases worldwide, famously leading to the …
greatly decreased the burden of infectious diseases worldwide, famously leading to the …
The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials
E Suder, W Furuyama, H Feldmann… - Human vaccines & …, 2018 - Taylor & Francis
The devastating Ebola virus (EBOV) epidemic in West Africa in 2013–2016 accelerated the
progress of several vaccines and antivirals through clinical trials, including the replication …
progress of several vaccines and antivirals through clinical trials, including the replication …
[HTML][HTML] Post-exposure treatments for Ebola and Marburg virus infections
RW Cross, CE Mire, H Feldmann… - Nature Reviews Drug …, 2018 - nature.com
The filoviruses—Ebola virus and Marburg virus—cause lethal haemorrhagic fever in
humans and non-human primates (NHPs). Filoviruses present a global health threat both as …
humans and non-human primates (NHPs). Filoviruses present a global health threat both as …
[HTML][HTML] Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus
Ebola virus (EBOV), a member of the family Filoviridae, is responsible for causing Ebola
virus disease (EVD)(formerly named Ebola hemorrhagic fever). This is a severe, often fatal …
virus disease (EVD)(formerly named Ebola hemorrhagic fever). This is a severe, often fatal …
[HTML][HTML] A VSV-based Zika virus vaccine protects mice from lethal challenge
J Emanuel, J Callison, KA Dowd, TC Pierson… - Scientific reports, 2018 - nature.com
Infection with Zika virus (ZIKV) is commonly mild in humans but has been associated with
alarming negative health outcomes including Guillain-Barré syndrome in adults and …
alarming negative health outcomes including Guillain-Barré syndrome in adults and …
Prevention of Ebola virus disease through vaccination: where we are in 2018
Y Lévy, C Lane, P Piot, AH Beavogui, M Kieh, B Leigh… - The Lancet, 2018 - thelancet.com
In 2016, Guinea, Liberia, and Sierra Leone succeeded in interrupting the longest epidemic
of Ebola virus disease in global history. 1 Control of the epidemic was primarily achieved by …
of Ebola virus disease in global history. 1 Control of the epidemic was primarily achieved by …
[HTML][HTML] Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort …
Background The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire
Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection …
Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection …
The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSV∆ G-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak
M Samai, JF Seward, ST Goldstein… - The Journal of …, 2018 - academic.oup.com
Abstract The West Africa Ebola epidemic stimulated rapid implementation of Ebola vaccine
trials in the 3 highly affected countries. In Sierra Leone, we studied the recombinant …
trials in the 3 highly affected countries. In Sierra Leone, we studied the recombinant …
[HTML][HTML] Ethical considerations in controlled human malaria infection studies in low resource settings: experiences and perceptions of study participants in a malaria …
Background: The range and amount of volunteer infection studies, known as Controlled
Human Infection Model (CHMI) studies, in Low-Middle Income Countries (LMICs) is …
Human Infection Model (CHMI) studies, in Low-Middle Income Countries (LMICs) is …
Ebola: lessons on vaccine development
H Feldmann, F Feldmann, A Marzi - Annual review of …, 2018 - annualreviews.org
The West African Ebola virus (EBOV) epidemic has fast-tracked countermeasures for this
rare, emerging zoonotic pathogen. Until 2013–2014, most EBOV vaccine candidates were …
rare, emerging zoonotic pathogen. Until 2013–2014, most EBOV vaccine candidates were …